LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.

Participants can access the conference call live via webcast on the Events page of the Company’s website at . Participants who wish to ask a question may to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website. 

About Lexicon Pharmaceuticals 

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit . 

For Investor and Media Inquiries: 

Lisa DeFrancesco

Lexicon Pharmaceuticals, Inc. 

 



EN
30/10/2025

Underlying

LXRXLexicon Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lexicon Pharmaceuticals Inc.

 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...

9h / 33m 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results a...

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of potential resubmission of Zynquista for type 1 diabetes submitted to FDA Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas,...

November 6, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient...

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitors THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) --   (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming medical meetings. Two studies will be presented at the American Heart Association’s (AHA) Scientific Sessions 2025, b...

November 4, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results...

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday, November 6, 2025, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s webs...

October 30, 2025 1 EN
 PRESS RELEASE
Free
LXRX Lexicon Pharmac...

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabet...

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit – Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 pilavapadin program at the 19th Annual Pain Therapeutics Summit. These data follow the  from the Phase 2b PROGRESS ...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch